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clinical response to treatment and the number of QALYs per patient accrued during 
the study. Only direct medical costs (drug acquisition, administration and hospitali-
zation costs) were incorporated in the model, as the analysis was conducted from a 
third-party payer perspective. With respect to administration cost, two alternative 
scenarios were considered in the base case analysis: administration in day-case unit 
and administration in the hospital outpatient department. Probabilistic sensitivity 
analysis was conducted. Primary outcomes were quality adjusted life years (QALYs) 
and incremental cost-effectiveness ratios (ICER). Results: In the base case analysis, 
QALYs of FCM treated patients were higher compared to no iron treated patients by 
0.04 QALYs. The total 24-week cost of FCM was higher by € 969 and € 204, it the two 
scenarios respectively. This difference was mainly attributed to the administration 
cost and drug acquisition cost related to FMC. Incremental cost effectiveness analysis 
showed that treatment with FCM was a cost-effective option resulting in an ICER 
of € 25,506 and € 5,368 per QALY gained in the scenarios respectively. Probabilistic 
sensitivity analysis revealed that FCM was likely to be cost-effective in over 80% and 
99% in the two scenarios respectively, at a willingness-to-pay threshold of € 34,000 
per QALY gained. ConClusions: Ferric carboxymaltose may be a cost – effective 
option in relation to no iron treatment for the management of iron deficiency of HF 
patients in Greece.
PCV81
Potential Cost-effeCtiVeness of theraPeutiC Drug Monitoring in 
Patients With resistant hyPertension
Chung O.1, Vongpatanasin W.2, Haverkamp W.1, Dorenkamp M.1
1Charite University Berlin, Campus Virchow-Klinikum, Berlin, Germany, 2University of Texas 
Southwestern Medical Center Dallas, Dallas, TX, USA
objeCtives: Non-adherence to drug therapy poses a significant problem in the treat-
ment of patients with presumed resistant hypertension (RH). It has been shown that 
therapeutic drug monitoring (TDM) is a useful tool for detecting non-adherence and 
identifying barriers to treatment adherence, leading to effective blood pressure (BP) 
control. However, the cost-effectiveness of TDM in the management of RH has not 
been investigated. Methods: A Markov model was used to evaluate life-years, qual-
ity-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios in RH 
patients receiving either TDM optimized therapy or standard best medical therapy. 
The model ran from the age of 30 to 100 years or death, using a cycle length of 1 year. 
Efficacy of TDM was modeled by reducing risk of hypertension-related morbidity and 
mortality. Cost analyses were performed from a payer’s perspective. Deterministic 
and probabilistic sensitivity analyses were conducted. Results: In the age group 
of 60-year olds, TDM gained 1.07 QALYs in men and 0.97 QALYs in women at addi-
tional costs of € 3,854 and € 3,922, respectively. Given a willingness-to-pay threshold 
of € 35,000 per QALY gained, the probability of TDM being cost-effective was ≥ 95% in 
all age groups from 30 to 90 years. Results were influenced mostly by the frequency 
of TDM testing, the rate of non-responders to TDM, and the magnitude of effect of 
TDM on BP. ConClusions: Therapeutic drug monitoring presents a potentialy highly 
cost-effective health care intervention in patients diagnosed with RH. Importantly, 
this finding is valid for a wide range of patients, independent of gender and age.
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objeCtives: SHIFT trial demonstrated that, by decreasing heart rate with 
Ivabradine, the incidence of events is reduced in patients with HF due to left ven-
tricular systolic disfunction (LVSD) and heart rate (HR) over 70 bpm. A cost-effective-
ness analysis demonstrating that this treatment strategy is cost-effective in United 
Kingdom has been published, but there are no publications with Spanish data. The 
objetive of this analysis is to determine whether treatment with Ivabradine in HF 
due to LVSD is a cost-effective strategy in Spain. Methods: A Markov model with 
three health states was built (baseline, admission due to HF and death), based on a 
simulated cohort of patients suffering HF due to LVSD and HR over 70 bpm, in order 
to compare the treatment strategies of the SHIFT trial, Ivabradine vs placebo, on top 
of standard treatment, was performed. A cost-efectiveness analysis with a life-time 
horizon, under the perspective of the NHS. Spanish costs were used to feed the 
model, and it was assumed that quality of life was worse during hospitalizations. 
A probabilistic sensitivity analysis was performed. The model took into account 
the incidence of complications related with HF (admission for HF, readmission for 
HF and death) and was fed with transition probabilities taken from the SHIFT trial 
and the SHIFT-hospitalization trial. Costs were obtained from cost data bases, the 
National Statistics Institute of Spain, institutions and scientific journals. Results: 
Cost per QALY of Ivabradine in comparison to placebo in heart failure due to left 
ventricular systolic disfunction is € 17,488 € , well below the acceptability threshold 
accepted in our enviroment (around 30,000 € ). Cost per LYG was € 13,044. Results 
were robust in the performed sensitivity analyses. ConClusions: In conclusion, 
treatment with Ivabradine in heart failure due to left ventricular systolic dysfunc-
tion is cost-effective in Spain.
PCV83
PharMaCoeConoMiC assessMent of aPixaban Versus stanDarD of 
Care for the PreVention of stroke in italian non-ValVular atrial 
fibrillation Patients
Pradelli L.1, Calandriello M.2, Di Virgilio R.3, Bellone M.1, Tubaro M4
1AdRes HE&OR, Turin, Italy, 2HE OR Unit - Bristol-Myers Squibb S. r. l., Rome, Italy, 3Pfizer 
Pharmaceuticals, Rome, Italy, 4San Filippo Neri Hospital, Rome, Italy
objeCtives: The objective of this study was to evaluate the cost-effectiveness 
of apixaban in the prevention of thromboembolic events in patients with non-
valvular atrial fibrillation (NVAF) relatively to standard of care (warfarin or aspirin) 
from the Italian National Health System (SSN) perspective. Methods: A previ-
ously published Markov model was adapted for Italian NVAF patients. Clinical 
were each asked to review a different batch of ECGs with differing proportions of AF 
and Sinus Rhythm (SR). ECGs were presented to the reviewers on two separate occa-
sions in two variations: full 12 lead and 10-second rhythm strip only. The diagnoses 
(AF/SR or unsure) were compared to a Consultant Cardiologist reading the 12-lead 
ECG. Results: Overall, compared to the Consultant Cardiologist, the AF detection 
rate using a 12-lead ECG was 81% and 82% with a rhythm strip. There was a signifi-
cant difference (chi squared test, p< 0.01) in AF detection rate when the reviewers 
were divided into 2 groups according to level of cardiology experience. The AF detec-
tion rate for the 12-lead ECG amongst specialists vs. non-specialists was 93% vs. 
70% (P< 0.001) and 92% vs. 73% (P= 0.003) for the rhythm strip. ConClusions: Our 
findings indicate that a 10-second rhythm strip alone has a comparable AF detection 
rate to a 12-lead ECG in the hands of doctors and nurses when measured against the 
consultant’s diagnosis. With both the rhythm strip and a 12-lead ECG, the accuracy 
of AF detection improved with experience. Mass screening using a single strip could 
be acceptable and inexpensive particularly with mobile phone technology.
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objeCtives: Hemostatic agents are used to stop intraoperative bleeding in the 
presence of actively flowing blood when applied directly to the bleeding site. Recent 
published literature on animal studies and real-world outcome data indicated that 
the hemostatic matrix agent Floseal could stop bleedings and reduce complications 
more effectively than Surgiflo with thrombin. The objective of this study is to quan-
tify cost consequences in the Netherlands when using Floseal versus Surgiflo with 
thrombin from a hospital perspective. Methods: A cost-consequence model was 
built based on a large retrospective analysis of a Premier’s US Hospital database to 
assess the value of using Floseal to achieve hemostasis in mixed cardiac surgery pro-
cedures relative to Surgiflo with thrombin. The model captures the cost implications 
on the following parameters: (1) operating room time; (2) postoperative bleeding-
related complication rates; (3) the need for surgical revisions due to bleeding, and; 
(4) the number of intraoperative and postoperative blood transfusions. Costs (€ ) 
were derived from published literature, the Dutch guideline for cost research and 
2014 national list prices. The model assumed a surgical case load of 100 mixed 
cardiac surgeries. Results: By reducing operating time, but moreover the number 
of complications, surgical revisions and blood products transfusion, Floseal can 
lead to a cost saving of € 2,933 per patient in comparison to the use of Surgiflo with 
thrombin. ConClusions: Our preliminary analysis indicates that using Floseal to 
stop intraoperative bleeding could lead to significant cost saving for the hospitals in 
the Netherlands. Further studies are required to confirm these findings.
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objeCtives: To evaluate cost-effectiveness of dabigatran and new oral antico-
agulants (NOA) compared to currently reimbursed warfarin and low molecular 
weight heparins (LMWH) for thromboembolic events prophylaxis from a payer’s 
perspective in Colombia. Methods: Markov decision model based on efficacy, 
utilities and safety inputs from clinical trials (CT) (RE-COVER I and II; Einstein-
DVT; Einstein-PE; AMPLIFY; RE-SONATE; RE-MEDY and a meta-analysis of 18 CT 
for LMWH. Cost of medication was obtained from SISMED, Vademecum Med®, 
and government reference prices; costs of events were estimated from hospital 
billing records, POS tariffs, SOAT Manual and local experts. Costs are reported in 
euros (1 € = COP 2,655) and effectiveness in terms of deaths due to bleeding and 
Quality Adjusted Life Years (QALYs). A 3% discount rate was used for costs and 
QALYs. A cohort of 1,000 patients, with similar demographic characteristics to 
those reported in the CT, was followed for a 5-year time horizon; with analysis for 6 
months, 1 year and lifetime. A univariate and probabilistic sensitivity analysis was 
performed. Results: Deaths due to bleeding were 5 with dabigatran, 7 with apixa-
ban, 9 with LMWH, 7 with rivaroxaban and 15 with warfarin, per 10,000 patients. 
Dabigatran is dominant compared with LMWH and apixaban. Compared with 
rivaroxaban, dabigatran is safer with similar costs and QALYs gained. Considering 
a base line scenario comparing all alternatives versus warfarin, dabigatrán dem-
onstrates the lowest ICER (€ 32,121/QALY) compared with rivaroxaban (€ 36,388/
QALY), apixaban (€ 72,228/QALY) and LMWH (€ 604,515/QALY). Our findings were 
consistent in the sensitivity analyses. ConClusions: Dabigatran is the alter-
native with the best value for money when all alternatives are compared with 
warfarin, and is dominant compared with LMWH, which are reimbursed by the 
current Colombian National Plan POS.
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objeCtives: To evaluate the cost-effectiveness of iron repletion with ferric carboxy-
maltorse (FCM), in iron-deficient heart failure (HF) patients in Greece. Methods: 
An international economic model was locally adapted to evaluate the use ferric car-
boxymaltorse to standard care over a time horizon of 24 weeks corresponding to the 
duration of the FAIR-HF trial. The efficacy of therapy was evaluated based on the 
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ing cardiovascular mortality, myocardial infarction (MI), or stroke among patients 
with acute coronary syndrome (ACS) compared to clopidogrel but without a signifi-
cant increase in major bleedings. In Hong Kong, generic clopidogrel was introduced 
in 2012. This study aimed to evaluate the long-term cost-effectiveness of ticagrelor 
in ACS patients in Hong Kong (HK) from a public hospital’s perspective. Methods: 
A two-phase Markov model was used to estimate the short- and long-term cost-
effectiveness measured as cost per quality-adjusted-life-year (QALY) and cost per 
life-year-gained (LYG) over 1 year, 5 years and patients’ lifetime. Direct medical costs 
were HK-specific and patients’ resource use, rate of cardiovascular events (i.e. MI 
and stroke) and utility data were from published literature. All costs were presented 
as 2014 figures, cost and effectiveness were both discounted at 3% per annum. 
Sensitivity analyses were performed to test model robustness. Results: Despite 
the great difference in the daily drug cost of ticagrelor and generic clopidogrel 
(US2.8, vs US0.10,1US= 7.8HK), the overall cost of management between the 2 groups 
remains similar. Our study shows that the incremental cost-effectiveness ratios 
(ICER) of ticagrelor were reduced substantially from US16,071/LYG and US19,493/
QALY in the first year to US302/LYG and US357/QALY over a lifetime time horizon 
due to improvements in health outcomes. The ICER values were all cost-effective 
based on the WHO 3xGDP criteria (GDP 2013= US37,860). The results are sensitive 
to cost of generic clopidogrel. ConClusions: Treating ACS patients with lifetime 
use of ticagrelor can potentially reduce the cost of management and increase the 
cost-effectiveness due to better health outcomes as compared to generic clopidogrel. 
Ticagrelor therapy appears to be cost-effective both on short- and long-term assess-
ment in the public health care sector of Hong Kong.
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objeCtives: The purpose of this project was to evaluate the incremental costs of 
increasing physical activity and improving body composition for a lifestyle walking 
program targeting sedentary African American women. Methods: The Women’s 
Lifestyle Physical Activity Program was a randomized behavioral trial that included 
a group intervention with social support and culturally relevant, tailored content 
about increasing physical activity and an automated telephone response system 
to track physical activity for sedentary African American women ages 40-65. The 
principal outcomes were change in minutes of walking and moderate and vigorous 
physical activity per week, and body mass index (BMI) between baseline and 24 
weeks. Incremental cost effectiveness ratios (ICER) were calculated for each out-
come.  The cost-effectiveness analysis included both program and participant costs 
and was calculated in 2013 US dollars. Results: For the 260 participants in the 
analysis, participant costs (e.g., group session attendance, logging physical activity 
in the ATR system) were $152 ± 42, while program costs (e.g., group session facilita-
tion, materials and supplies) were $164 ± 21, for a total cost of $316 ± 59. Walking 
increased by 200 minutes per week at 24 week, with an ICER of $1.64 (95% CI, 1.63 
– 1.66) per minute, moderate and vigorous physical activity increased by 117 min-
utes per week, with an ICER of $2.79 per minute, and BMI decreased by 0.09 points, 
with an ICER of $3463 (95% CI, 500 – 9,540) per 1-point reduction. ConClusions: 
The Women’s Lifestyle Physical Activity Program is a relatively low cost strategy for 
increasing physical activity. The incremental cost of increasing walking minutes 
is substantially lower than for moderate and vigorous physical activity. The par-
ticipant costs related to time in the program were more than half of the total costs, 
suggesting that practitioners and policymakers should consider the participant cost 
when disseminating group programs into practice.
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objeCtives: The study assessed the lifetime cost-effectiveness of apixaban in pre-
venting thromboembolic events in non-valvular atrial fibrillation (NVAF) patients, 
as compared to other novel oral anticoagulant agents (NOACs), from the Italian 
Health System (SSN) perspective. Methods: A previously published Markov 
model was adapted. Baseline clinical risks were assigned based on the demo-
graphic and clinical features of the patients; effectiveness parameters derived 
from adjusted indirect comparison using warfarin as link. Expected survival 
was projected beyond trial duration using national mortality data adjusted for 
clinical risks and weighted by published utilities. Unit costs were collected from 
official and published Italian sources. Costs (2013-€ ) and health gains occurring 
after the first year were discounted at an annual 3.5% rate. Deterministic and 
probabilistic sensitivity analyses (DSA&PSA) were carried out. Results: In the 
short to medium term, apixaban was associated with marginal LYs and QALYs 
gains and slight savings. However, as apixaban extended expected survival ver-
sus dabigatran (110mg), dabigatran (150mg) and rivaroxaban (0.13,0. 08, and 0.06 
LYs or 0.11,0. 07, and 0.05 QALYs), expected total lifetime costs exceeded those of 
these comparators (319,282,16 € ). Corresponding ICERs were estimated in € 2,911, 
€ 3,882 and € 327 per QALY gained. In PSA, the probabilities of apixaban being cost 
effective with a WTP threshold of 20,000 € /QALY gained were 99%, 92% and 93% 
for the same comparisons. The most influential parameter according to DSA was 
daily cost of NOACs, but the corresponding ICERs remained well below commonly 
accepted WTP values. ConClusions: Apixaban is expected to be more effective 
than dabigatran and rivaroxaban in Italian NVAF patients, and marginally more 
costly due to costs in added years of life. The ICERs have a high likelihood of being 
below conventional thresholds of WTP for health benefits of the SSN and suggest 
that apixaban is cost-effective compared with other NOACs.
effectiveness data were derived from head-to-head randomized trials (ARISTOTLE 
and AVERROES); main events considered in the model were ischemic and hemor-
rhagic stroke, systemic thromboembolism, bleeds (both major and clinically rel-
evant minor) and cardiovascular hospitalizations. Expected survival was projected 
beyond trial duration using national mortality data adjusted for individual clinical 
risks and adjusted by utility weights for health states derived from literature. Unit 
costs were collected from published Italian sources. Costs (2013 € ) and health gains 
accruing after the first year were discounted at an annual 3.5% rate. Deterministic 
and probabilistic sensitivity analyses (PSA) were carried out to assess the effect of 
input uncertainty. Results: Incremental LYs (0.31/0.19), QALYs (0.28/0.20), and costs 
(1,932/1,104) are predicted with the use of apixaban relative to aspirin and warfarin, 
respectively. The incremental cost effectiveness ratios (ICERs) of apixaban were € 
6,794 and € 5,607 per QALY gained, respectively. In PSA, the probability of apixaban 
being cost effective relative to aspirin and warfarin was 95% and 93%, respectively, 
for a WTP threshold of € 20,000 per QALY gained. Univariate analyses indicate that 
results were most sensitive to variations of the absolute risk reduction for cardiovas-
cular events with apixaban. ConClusions: Apixaban is expected to increase life 
expectancy and quality-adjusted life expectancy, but also costs dedicated to Italian 
NVAF patients, as compared to standard of care. The resulting ICERs have high prob-
abilities of being below the conventional thresholds of WTP for health benefits of 
the SSN, indicating efficient allocation of health care resources.
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objeCtives: Systematic anticoagulation management clinic is now recom-
mended to manage warfarinized atrial fibrillation (AF) patient. In Malaysia, the 
service is recently introduced as pharmacist managed Warfarin Medication Therapy 
Adherence Clinic (WMTAC). The objective of the present study was to assess the 
cost effectiveness of anticoagulation clinic in comparison with usual medical 
in Kuala Lumpur Hospital. Methods: A Markov model built using the provider 
perspective and 20 year time horizon was used to assess the cost effectiveness. 
The base case analysis assumed a cohort of patients with AF 57 years of age with 
comorbid illnesses. Data sources include a 6 month retrospective cohort analysis 
of the effectiveness of the clinics, the cost of drugs, cost of personnel and space 
of the clinics, cost of monitoring and cost of adverse events were obtained from 
the local source and publications. The transition probabilities of these clinics out-
comes were obtained from a literature search. Future costs were discounted by 
3% to convert to present values. All costs were in Ringgit Malaysia (RM) based on 
year 2012. Results: The results of a 20-year period model showed that UMC was 
dominated by the WMTAC in the same time period. The mean cost of the WMTAC 
was RM 5864 whereas the UMC cost was RM 6550. The sensitivity analysis showed 
that clinic treatment costs and effectiveness influenced the cost-effectiveness. If the 
cost of WMTAC was increased by 50% of the current cost, the WMTAC would not be 
a dominant intervention. WMTAC was also cost effective for a willingness to pay of 
RM32000. ConClusions: The anticoagulation management service appears to cost 
less and provide greater effectiveness than usual care. In conclusion, the Markov 
model suggests that from the provider perspective the anticoagulation clinic is a 
more cost effective option than the usual medical clinic in Kuala Lumpur Hospital.
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objeCtives: To assess cost-effectiveness of ranolazine in Russian patients with 
angina pectoris. Methods: A model was developed to compare a strategy of treat-
ment of angina pectoris with ranolazine and a traditional therapy in patients with 
at least 3 heart attacks per week. The analysis was based on the results of ERICA 
(Efficacy of Ranolazine in Chronic Angina) study that included Russian patients and 
reflected a routine Russian practice for the treatment of the disease. The analysis 
included costs of drug therapy, emergency care and hospitalization. Effectiveness 
rate was measured as a change of frequency of angina attacks compared to initial 
level estimated by SAQ (Seattle Angina Questionnaire). Sensitivity analysis con-
sidered the change of parameters in different length of hospitalization. Results: 
Total costs in ranolazine group were insignificanlty higher than in control group 
(573.84 RUB per patient). At the same time, ranolazine changed the structure of 
costs: expenditures on medications grew while costs of emergency care and hos-
pitalization reduced. CER value was 1640.86 in ranolazine group, and 1964.63 (1.2 
times less) in group of traditional therapy. The change of hospitalization length in 
sensitivity analysis was also more favorable in case of ranolazine: 164 479.81 vs 
197 300.02 RUB/unit, which confirms previous results. ConClusions: The use of 
ranolazine in patients with > 3 heart attacks of angina pectoris per week is clinically 
and economically substantiated.
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objeCtives: The multi-centered, double-blind, randomized PLATO trial on 18,624 
patients from 43 countries has demonstrated that ticagrelor was superior in reduc-
